丁苯酞氯化钠注射液联合依达拉奉治疗新发脑梗死的疗效及神经功能和CRP水平分析

发布时间：2018-03-28 13:17

本文选题：丁苯酞氯化钠注射液　切入点：依达拉奉　出处：《中国新药杂志》2017年23期

【摘要】：目的:研究丁苯酞氯化钠注射液(恩必普)联合依达拉奉治疗新发脑梗死的疗效及其对神经功能和CRP水平的影响。方法:选取2015年5月至2017年2月无锡市人民医院收治的64例新发脑梗死患者,按照随机数表法分为试验组和对照组,每组32例。对照组用依达拉奉治疗(30 mg,bid),试验组在对照组基础上联合恩必普注射液(100 m L,bid)进行治疗,所有患者疗程均为10 d。比较患者治疗前后CRP水平、神经功能和日常生活能力变化,观察患者的临床疗效和不良反应。结果:治疗后10 d,试验组的CRP水平明显低于对照组[(25.32±2.43)mg·L~(-1)vs(45.11±5.32)mg·L~(-1)],组间比较差异性明显(P0.05)。试验组的NIHSS评分明显低于对照组[(12.45±2.31)分vs(16.32±3.56)分],BI评分明显高于对照组[(80.32±7.15)分vs(50.87±5.35)分],组间比较差异明显(P0.05)。试验组总的临床疗效率明显高于对照组[90.62%(29/32)vs 53.12%(17/32)](P0.05)。结论:与单独使用依达拉奉相比,恩必普联合依达拉奉治疗新发脑梗死患者能明显改善患者的神经功能和CRP水平。
[Abstract]:Objective: To study the Butylphthalide and Sodium Chloride Injection (dl-3-butylphthalide) combined with edaravone in treatment of cerebral infarction and its effect on the nervous function and the level of CRP. Methods: from May 2015 to February 2017 in Wuxi City People's hospital treated 64 cases of cerebral infarction were randomly divided into experimental group and control group, 32 cases in each group. The control group edaravone (30 mg, bid), the experimental group in the control group based on the combination of butylphthalide injection (100 m L, bid) treatment, all patients were treated for 10 d. before and after treatment in patients with CRP compared the level, changes of nerve function and ability of daily living, and adverse reactions were observed in patients with clinical efficacy. Results: after the treatment of 10 d, CRP of the test group was significantly lower than the control group [(25.32 + 2.43) Mg - L~ (-1) vs (45.11 + 5.32) Mg - L~ (-1)], the difference between groups was significant (P0.05). The NIHSS score of the experimental group was significantly lower In the control group [(12.45 + 2.31) vs (16.32 + 3.56)%], the BI score was significantly higher than the control group [(80.32 + 7.15) vs (50.87 + 5.35)%], significant differences between the two groups (P0.05). The experimental group the total clinical efficiency was significantly higher than the control group (29/32 [90.62% vs 53.12% (17/) 32)] (P0.05). Conclusion: compared with edaravone alone, butylphthalide combined with edaravone in treatment of cerebral infarction patients can significantly improve the neurological function and the level of CRP.

【作者单位】：苏州大学附属第一医院神经内科;无锡市人民医院神经内科;
【分类号】：R743.33

【相似文献】